<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03821597</url>
  </required_header>
  <id_info>
    <org_study_id>Swanson 010</org_study_id>
    <nct_id>NCT03821597</nct_id>
  </id_info>
  <brief_title>Sequential Compression Devices Effect on Fibrinolysis in Plastic Surgery Outpatients</brief_title>
  <official_title>The Effect of Intraoperative Sequential Compression Devices on Fibrinolysis in Plastic Surgery Outpatients: A Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swanson Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swanson Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates a possible fibrinolytic effect of sequential compression devices&#xD;
      (SCDs). These devices have been used for decades to reduce risk of deep venous thrombosis&#xD;
      (DVT). However, a randomized study in plastic surgery outpatients has not been done. This&#xD;
      study is undertaken to remedy that deficiency in our knowledge base.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol: The Effect of Intraoperative Sequential Compression Devices on Fibrinolysis in&#xD;
      Plastic Surgery Outpatients&#xD;
&#xD;
        1. Study Synopsis&#xD;
&#xD;
           Deep venous thrombosis (DVT) is a serious and potentially life-threatening surgical&#xD;
           complication. Sequential compression devices (SCDs), also called intermittent pneumatic&#xD;
           compression, are widely used by surgeons in an effort to reduce risk. In addition to a&#xD;
           possible mechanical effect, some investigators believe that these devices reduce the&#xD;
           coagulability of blood by altering the fibrinolytic balance. This investigation is meant&#xD;
           to evaluate any possible effect of these devices on fibrinolytic activity.&#xD;
&#xD;
           The SCDs are not being investigated for a new indication. This study is meant to&#xD;
           determine whether these commonly used devices have any effect on blood coagulability.&#xD;
           This study is not intended to determine whether SCDs affect DVT rates.&#xD;
&#xD;
        2. Background&#xD;
&#xD;
           The investigator (ES) has conducted a literature search on this topic. There is no&#xD;
           published prospective randomized study available investigating a possible fibrinolytic&#xD;
           effect of SCDs in surgical patients. Therefore any clinical benefit remains speculative.&#xD;
&#xD;
        3. Objective&#xD;
&#xD;
           The use of this device is well-recognized. The rationale for using SCDs in this study is&#xD;
           to investigate their potential effect on blood coagulability.&#xD;
&#xD;
        4. Subject Selection&#xD;
&#xD;
           The proposed study is a prospective randomized study involving 50 consecutive plastic&#xD;
           surgery outpatients who consent to participate. Twenty-five patients will have&#xD;
           sequential compression devices applied and 25 patients will not be treated with these&#xD;
           devices and will serve as controls. All subjects are adults aged 18 or over undergoing&#xD;
           elective cosmetic surgery, including both men and women.&#xD;
&#xD;
           All patients, men and women, are included with no exclusion criteria (that go beyond&#xD;
           exclusion criteria for elective outpatient surgery). Pregnant women are not surgical&#xD;
           candidates and are excluded (women in the reproductive age group are routinely checked&#xD;
           with a pregnancy test). There are no contraindications to SCDs among patients undergoing&#xD;
           elective outpatient plastic surgery. Patients with coagulopathies that would represent a&#xD;
           contraindication for surgery, or significant diseases (heart disease, uncontrolled&#xD;
           diabetes) are excluded. Oral contraceptive use is permitted.&#xD;
&#xD;
           The purpose of including patients who are not treated with SCDs is to have a control&#xD;
           group, which is mandatory in a randomized study. The sample size of 50 was obtained from&#xD;
           an a priori power analysis and sample size calculation to allow statistical significance&#xD;
           at an alpha value of 0.05. The use of SCDs is not a standard of care requirement. Their&#xD;
           efficacy remains controversial, with no high-level (i.e. Level 1) support.&#xD;
&#xD;
           All patients receive measures to reduce the risk of DVT. No muscle relaxation is used&#xD;
           during surgery to preserve the calf muscle pump. Patients ambulate immediately after&#xD;
           surgery. In addition, patients are monitored with ultrasound surveillance to ensure the&#xD;
           early detection and treatment of any DVTs that may develop postoperatively. Patients do&#xD;
           not normally receive anti-platelet therapy because of the increased risk of bleeding.&#xD;
&#xD;
           Patients with contraindications to the use of SCDs will be excluded from the study.&#xD;
           These conditions include suspected active or untreated DVT, pulmonary edema, congestive&#xD;
           heart failure, thrombophlebitis or an active infection, vein ligation, gangrene,&#xD;
           dermatitis, open wounds, a recent skin graft, massive edema or extreme deformity of the&#xD;
           leg, neuropathy, legs that are insensitive to pain, or when increased venous or&#xD;
           lymphatic return is undesirable. None of these conditions is present in healthy patients&#xD;
           undergoing elective cosmetic surgery, which form the study group.&#xD;
&#xD;
        5. Study Procedures&#xD;
&#xD;
           The duration of the study is 2 months, sufficient to obtain data for 50 consecutive&#xD;
           patients. All patients are plastic surgery outpatients undergoing elective cosmetic&#xD;
           procedures. The consent discussion will take place between the principal investigator&#xD;
           and the patient. All surgery will be performed by the study author at a state-licensed&#xD;
           ambulatory surgery center, the Surgery Center of Leawood, KS.&#xD;
&#xD;
           Patients already have IV access at the time of surgery. A blood sample (2 cc) will be&#xD;
           drawn immediately before surgery and at 1-hour intervals during surgery and in the&#xD;
           recovery room. The blood samples will be analyzed at an outside laboratory for tissue&#xD;
           plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels at&#xD;
           these time points. The number of blood draws will be determined by the length of the&#xD;
           operation and time in the recovery room. The last blood sample is taken at the hourly&#xD;
           interval that immediately precedes the patient's discharge from the recovery room.&#xD;
&#xD;
           All patients will undergo ultrasound surveillance. This diagnostic test is painless,&#xD;
           noninvasive, and highly accurate for detecting DVTs. Scans are performed before surgery,&#xD;
           on the day after surgery, and 1 week after surgery.&#xD;
&#xD;
        6. Risk/Safety Information&#xD;
&#xD;
           There is no risk or discomfort to the patient and the amount of blood drawn is&#xD;
           minuscule. There added risks associated with SCD sleeves are very rare, such as skin&#xD;
           irritation, nerve compression, and patient falls, although the latter problem is&#xD;
           impossible because the devices are removed prior to the patient waking up from surgery.&#xD;
&#xD;
        7. Monitoring/Reporting of Adverse Events&#xD;
&#xD;
           Any adverse event will be monitored by the principal investigator and reported to&#xD;
           patients, although none is expected. The principal investigator will collect, assess,&#xD;
           and follow-up on any adverse events. Any adverse events will be reported, including to&#xD;
           the Institutional Review Board (IRB) and regulatory authorities.&#xD;
&#xD;
        8. Study Oversight&#xD;
&#xD;
           There are no foreseeable circumstances that would abort the study. The study and data&#xD;
           will be available for auditing.&#xD;
&#xD;
           Data Management&#xD;
&#xD;
        9. Data will be analyzed by a biostatistician.&#xD;
&#xD;
       10. IRB Review/Ethics Informed Consent&#xD;
&#xD;
           This study meets the standard of equipoise in that there is no known benefit of SCDs in&#xD;
           preventing DVTs in plastic surgery outpatients. SCDs harmlessly compress the calves and&#xD;
           are known to be extremely safe. Each subject will receive full and adequate verbal and&#xD;
           written information. Consenting patients will read and sign the Informed Consent&#xD;
           document prior to taking part in the study and prior to surgery. Any change in the&#xD;
           protocol will be submitted for review. This study is undertaken in accordance with&#xD;
           ethical principles that have their origin in the Declaration of Helsinki and are&#xD;
           consistent with Good Clinical Practice and applicable regulatory requirements. This&#xD;
           study will be conducted in accordance with the regulations of the U.S. Food and Drug&#xD;
           Administration (FDA) applicable laws and IRB requirement.&#xD;
&#xD;
       11. Confidentiality&#xD;
&#xD;
           Pooled data will be evaluated without any identifying information by a Ph.D.&#xD;
           biostatistician. There is no opportunity for violation of patient privacy. Blood samples&#xD;
           will only include a number (Patient 1, patient 2, etc.) and the date and time of the&#xD;
           blood draw with no patient identifying information sent to the lab (Quest Laboratories).&#xD;
           Patient information is kept within a secure location within the office of the principal&#xD;
           investigator in accordance with HIPAA requirements. No patient identification will&#xD;
           accompany any publications of the study. The data are open to inspection by any&#xD;
           regulatory authorities.&#xD;
&#xD;
       12. Intended Use of the Data&#xD;
&#xD;
      The data will be evaluated to determine whether or not the null hypothesis is confirmed (i.e.&#xD;
      whether SCDs affect blood coagulability). It is expected that the study findings will be&#xD;
      published in the medical literature.&#xD;
&#xD;
      Disclosure&#xD;
&#xD;
      The author has no financial interest in any of the products, devices, or drugs used in this&#xD;
      study. The author has no conflicts of interest to disclose. The investigator has no financial&#xD;
      interest in ultrasound or the device used. There is no outside funding for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">January 27, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomized, controlled study.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1</measure>
    <time_frame>1-2 months</time_frame>
    <description>Laboratory testing of serum levels</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Blood Coagulation Disorder</condition>
  <arm_group>
    <arm_group_label>Sequential compression devices</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential compression devices (SCDs) are applied during surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No sequential compression devices</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>No sequential compression devices are applied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sequential compression devices (SCDs)</intervention_name>
    <description>Application of sequential compression devices in surgery.</description>
    <arm_group_label>Sequential compression devices</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>No sequential compression.</intervention_name>
    <description>No sequential compression devices are applied.</description>
    <arm_group_label>No sequential compression devices</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All healthy patients aged 18 or more.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  These conditions include suspected active or untreated DVT, pulmonary edema,&#xD;
             congestive heart failure, thrombophlebitis or an active infection, vein ligation,&#xD;
             gangrene, dermatitis, open wounds, a recent skin graft, massive edema or extreme&#xD;
             deformity of the leg, neuropathy, legs that are insensitive to pain, or when increased&#xD;
             venous or lymphatic return is undesirable.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Swanson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Swanson Cener</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Swanson Center</name>
      <address>
        <city>Leawood</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Comerota AJ, Chouhan V, Harada RN, Sun L, Hosking J, Veermansunemi R, Comerota AJ Jr, Schlappy D, Rao AK. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg. 1997 Sep;226(3):306-13; discussion 313-4. doi: 10.1097/00000658-199709000-00010.</citation>
    <PMID>9339937</PMID>
  </reference>
  <reference>
    <citation>Swanson E. Do Sequential Compression Devices Really Reduce the Risk of Venous Thromboembolism in Plastic Surgery Patients? Plast Reconstr Surg. 2015 Oct;136(4):577e-578e. doi: 10.1097/PRS.0000000000001587. No abstract available.</citation>
    <PMID>26114974</PMID>
  </reference>
  <reference>
    <citation>Murphy RX Jr, Alderman A, Gutowski K, Kerrigan C, Rosolowski K, Schechter L, Schmitz D, Wilkins E. Evidence-based practices for thromboembolism prevention: summary of the ASPS Venous Thromboembolism Task Force Report. Plast Reconstr Surg. 2012 Jul;130(1):168e-175e. doi: 10.1097/PRS.0b013e318254b4ee.</citation>
    <PMID>22743901</PMID>
  </reference>
  <reference>
    <citation>Swanson E. Ultrasound screening for deep venous thrombosis detection: a prospective evaluation of 200 plastic surgery outpatients. Plast Reconstr Surg Glob Open. 2015 Apr 7;3(3):e332. doi: 10.1097/GOX.0000000000000311. eCollection 2015 Mar.</citation>
    <PMID>25878943</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 27, 2019</study_first_submitted>
  <study_first_submitted_qc>January 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>January 29, 2019</last_update_submitted>
  <last_update_submitted_qc>January 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fibrinolysis, sequential compression devices</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatic Disorders</mesh_term>
    <mesh_term>Blood Coagulation Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03821597
org study id: Swanson 010
nct id: NCT03821597
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
This study investigates a possible fibrinolytic effect of sequential compression devices
      (SCDs). These devices have been used for decades to reduce risk of deep venous thrombosis
      (DVT). However, a randomized study in plastic surgery outpatients has not been done. This
      study is undertaken to remedy that deficiency in our knowledge base.
Protocol: The Effect of Intraoperative Sequential Compression Devices on Fibrinolysis in
      Plastic Surgery Outpatients

        1. Study Synopsis

           Deep venous thrombosis (DVT) is a serious and potentially life-threatening surgical
           complication. Sequential compression devices (SCDs), also called intermittent pneumatic
           compression, are widely used by surgeons in an effort to reduce risk. In addition to a
           possible mechanical effect, some investigators believe that these devices reduce the
           coagulability of blood by altering the fibrinolytic balance. This investigation is meant
           to evaluate any possible effect of these devices on fibrinolytic activity.

           The SCDs are not being investigated for a new indication. This study is meant to
           determine whether these commonly used devices have any effect on blood coagulability.
           This study is not intended to determine whether SCDs affect DVT rates.

        2. Background

           The investigator (ES) has conducted a literature search on this topic. There is no
           published prospective randomized study available investigating a possible fibrinolytic
           effect of SCDs in surgical patients. Therefore any clinical benefit remains speculative.

        3. Objective

           The use of this device is well-recognized. The rationale for using SCDs in this study is
           to investigate their potential effect on blood coagulability.

        4. Subject Selection

           The proposed study is a prospective randomized study involving 50 consecutive plastic
           surgery outpatients who consent to participate. Twenty-five patients will have
           sequential compression devices applied and 25 patients will not be treated with these
           devices and will serve as controls. All subjects are adults aged 18 or over undergoing
           elective cosmetic surgery, including both men and women.

           All patients, men and women, are included with no exclusion criteria (that go beyond
           exclusion criteria for elective outpatient surgery). Pregnant women are not surgical
           candidates and are excluded (women in the reproductive age group are routinely checked
           with a pregnancy test). There are no contraindications to SCDs among patients undergoing
           elective outpatient plastic surgery. Patients with coagulopathies that would represent a
           contraindication for surgery, or significant diseases (heart disease, uncontrolled
           diabetes) are excluded. Oral contraceptive use is permitted.

           The purpose of including patients who are not treated with SCDs is to have a control
           group, which is mandatory in a randomized study. The sample size of 50 was obtained from
           an a priori power analysis and sample size calculation to allow statistical significance
           at an alpha value of 0.05. The use of SCDs is not a standard of care requirement. Their
           efficacy remains controversial, with no high-level (i.e. Level 1) support.

           All patients receive measures to reduce the risk of DVT. No muscle relaxation is used
           during surgery to preserve the calf muscle pump. Patients ambulate immediately after
           surgery. In addition, patients are monitored with ultrasound surveillance to ensure the
           early detection and treatment of any DVTs that may develop postoperatively. Patients do
           not normally receive anti-platelet therapy because of the increased risk of bleeding.

           Patients with contraindications to the use of SCDs will be excluded from the study.
           These conditions include suspected active or untreated DVT, pulmonary edema, congestive
           heart failure, thrombophlebitis or an active infection, vein ligation, gangrene,
           dermatitis, open wounds, a recent skin graft, massive edema or extreme deformity of the
           leg, neuropathy, legs that are insensitive to pain, or when increased venous or
           lymphatic return is undesirable. None of these conditions is present in healthy patients
           undergoing elective cosmetic surgery, which form the study group.

        5. Study Procedures

           The duration of the study is 2 months, sufficient to obtain data for 50 consecutive
           patients. All patients are plastic surgery outpatients undergoing elective cosmetic
           procedures. The consent discussion will take place between the principal investigator
           and the patient. All surgery will be performed by the study author at a state-licensed
           ambulatory surgery center, the Surgery Center of Leawood, KS.

           Patients already have IV access at the time of surgery. A blood sample (2 cc) will be
           drawn immediately before surgery and at 1-hour intervals during surgery and in the
           recovery room. The blood samples will be analyzed at an outside laboratory for tissue
           plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) levels at
           these time points. The number of blood draws will be determined by the length of the
           operation and time in the recovery room. The last blood sample is taken at the hourly
           interval that immediately precedes the patient's discharge from the recovery room.

           All patients will undergo ultrasound surveillance. This diagnostic test is painless,
           noninvasive, and highly accurate for detecting DVTs. Scans are performed before surgery,
           on the day after surgery, and 1 week after surgery.

        6. Risk/Safety Information

           There is no risk or discomfort to the patient and the amount of blood drawn is
           minuscule. There added risks associated with SCD sleeves are very rare, such as skin
           irritation, nerve compression, and patient falls, although the latter problem is
           impossible because the devices are removed prior to the patient waking up from surgery.

        7. Monitoring/Reporting of Adverse Events

           Any adverse event will be monitored by the principal investigator and reported to
           patients, although none is expected. The principal investigator will collect, assess,
           and follow-up on any adverse events. Any adverse events will be reported, including to
           the Institutional Review Board (IRB) and regulatory authorities.

        8. Study Oversight

           There are no foreseeable circumstances that would abort the study. The study and data
           will be available for auditing.

           Data Management

        9. Data will be analyzed by a biostatistician.

       10. IRB Review/Ethics Informed Consent

           This study meets the standard of equipoise in that there is no known benefit of SCDs in
           preventing DVTs in plastic surgery outpatients. SCDs harmlessly compress the calves and
           are known to be extremely safe. Each subject will receive full and adequate verbal and
           written information. Consenting patients will read and sign the Informed Consent
           document prior to taking part in the study and prior to surgery. Any change in the
           protocol will be submitted for review. This study is undertaken in accordance with
           ethical principles that have their origin in the Declaration of Helsinki and are
           consistent with Good Clinical Practice and applicable regulatory requirements. This
           study will be conducted in accordance with the regulations of the U.S. Food and Drug
           Administration (FDA) applicable laws and IRB requirement.

       11. Confidentiality

           Pooled data will be evaluated without any identifying information by a Ph.D.
           biostatistician. There is no opportunity for violation of patient privacy. Blood samples
           will only include a number (Patient 1, patient 2, etc.) and the date and time of the
           blood draw with no patient identifying information sent to the lab (Quest Laboratories).
           Patient information is kept within a secure location within the office of the principal
           investigator in accordance with HIPAA requirements. No patient identification will
           accompany any publications of the study. The data are open to inspection by any
           regulatory authorities.

       12. Intended Use of the Data

      The data will be evaluated to determine whether or not the null hypothesis is confirmed (i.e.
      whether SCDs affect blood coagulability). It is expected that the study findings will be
      published in the medical literature.

      Disclosure

      The author has no financial interest in any of the products, devices, or drugs used in this
      study. The author has no conflicts of interest to disclose. The investigator has no financial
      interest in ultrasound or the device used. There is no outside funding for this study.
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: Prospective, randomized, controlled study.
primary purpose: Prevention
masking: None (Open Label)
measure: Change in plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1
time frame: 1-2 months
description: Laboratory testing of serum levels
arm group label: Sequential compression devices
arm group type: Experimental
description: Sequential compression devices (SCDs) are applied during surgery.
arm group label: No sequential compression devices
arm group type: Active Comparator
description: No sequential compression devices are applied.
intervention type: Procedure
intervention name: Sequential compression devices (SCDs)
description: Application of sequential compression devices in surgery.
arm group label: Sequential compression devices
intervention type: Procedure
intervention name: No sequential compression.
description: No sequential compression devices are applied.
arm group label: No sequential compression devices
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
last name: Eric Swanson, M.D.
role: Principal Investigator
affiliation: Swanson Cener
facility: 
country: United States
citation: Comerota AJ, Chouhan V, Harada RN, Sun L, Hosking J, Veermansunemi R, Comerota AJ Jr, Schlappy D, Rao AK. The fibrinolytic effects of intermittent pneumatic compression: mechanism of enhanced fibrinolysis. Ann Surg. 1997 Sep;226(3):306-13; discussion 313-4. doi: 10.1097/00000658-199709000-00010.
PMID: 9339937
citation: Swanson E. Do Sequential Compression Devices Really Reduce the Risk of Venous Thromboembolism in Plastic Surgery Patients? Plast Reconstr Surg. 2015 Oct;136(4):577e-578e. doi: 10.1097/PRS.0000000000001587. No abstract available.
PMID: 26114974
citation: Murphy RX Jr, Alderman A, Gutowski K, Kerrigan C, Rosolowski K, Schechter L, Schmitz D, Wilkins E. Evidence-based practices for thromboembolism prevention: summary of the ASPS Venous Thromboembolism Task Force Report. Plast Reconstr Surg. 2012 Jul;130(1):168e-175e. doi: 10.1097/PRS.0b013e318254b4ee.
PMID: 22743901
citation: Swanson E. Ultrasound screening for deep venous thrombosis detection: a prospective evaluation of 200 plastic surgery outpatients. Plast Reconstr Surg Glob Open. 2015 Apr 7;3(3):e332. doi: 10.1097/GOX.0000000000000311. eCollection 2015 Mar.
PMID: 25878943
responsible party type: Sponsor
mesh term: Hemostatic Disorders
mesh term: Blood Coagulation Disorders
sharing ipd: No